Growing community of inventors

Victoria, Australia

Nina Wilkins

Average Co-Inventor Count = 5.56

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 44

Nina WilkinsIgor Gonda (3 patents)Nina WilkinsAdam Watkinson (3 patents)Nina WilkinsKerrie Setiawan (3 patents)Nina WilkinsTony Dipietro (3 patents)Nina WilkinsAndrew Humberstone (3 patents)Nina WilkinsBarrie Charles Finnin (2 patents)Nina WilkinsTimothy Matthias Morgan (2 patents)Nina WilkinsBarry Leonard Reed (2 patents)Nina WilkinsKathryn Traci-Jane Klose (1 patent)Nina WilkinsKathryn Taci-Jane Klose (1 patent)Nina WilkinsIgor Gonda (0 patent)Nina WilkinsMonique Robinson (0 patent)Nina WilkinsTony Di Pietro (0 patent)Nina WilkinsCarolyn Stone (0 patent)Nina WilkinsNina Wilkins (5 patents)Igor GondaIgor Gonda (54 patents)Adam WatkinsonAdam Watkinson (7 patents)Kerrie SetiawanKerrie Setiawan (4 patents)Tony DipietroTony Dipietro (3 patents)Andrew HumberstoneAndrew Humberstone (3 patents)Barrie Charles FinninBarrie Charles Finnin (14 patents)Timothy Matthias MorganTimothy Matthias Morgan (13 patents)Barry Leonard ReedBarry Leonard Reed (13 patents)Kathryn Traci-Jane KloseKathryn Traci-Jane Klose (6 patents)Kathryn Taci-Jane KloseKathryn Taci-Jane Klose (1 patent)Igor GondaIgor Gonda (0 patent)Monique RobinsonMonique Robinson (0 patent)Tony Di PietroTony Di Pietro (0 patent)Carolyn StoneCarolyn Stone (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Acrux Dds Pty Ltd (4 from 24 patents)

2. Acrux Dds Pty Ltc. (1 from 1 patent)


5 patents:

1. 9180194 - Method and composition for transdermal drug delivery

2. 8993520 - Method and composition for transdermal drug delivery

3. 8784878 - Transdermal delivery rate control using amorphous pharmaceutical compositions

4. 8435944 - Method and composition for transdermal drug delivery

5. 8357393 - Transdermal delivery rate control using amorphous pharmaceutical compositions

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/5/2026
Loading…